Braidwell LP Acquires $32.9M Stake in Dianthus Therapeutics

Institutional investor takes major position in biotech firm as it advances clinical programs

Mar. 15, 2026 at 8:57am

Got story updates? Submit your updates here. ›

Braidwell LP, an investment management firm, has acquired a new stake of 835,057 shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company developing complement therapeutics. The stake is valued at approximately $32.9 million, representing 1.95% ownership of Dianthus Therapeutics.

Why it matters

The investment by Braidwell LP, a prominent institutional investor, signals confidence in Dianthus Therapeutics' pipeline and future prospects. Dianthus is advancing its lead candidate DNTH103, a monoclonal antibody, through Phase 2 clinical trials for the treatment of autoimmune and inflammatory diseases. This sizable investment could provide the company with additional resources to support its clinical development efforts.

The details

According to a recent 13F filing, Braidwell LP acquired the 835,057 shares of Dianthus Therapeutics in the third quarter. The purchase represents a significant stake valued at around $32.9 million, or 1.95% of the company's outstanding shares. Other major institutional investors in Dianthus include Wellington Management Group, Vestal Point Capital, and Franklin Resources.

  • Braidwell LP acquired the stake in Dianthus Therapeutics during the third quarter of the year.

The players

Braidwell LP

An investment management firm that has acquired a new stake in Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

A clinical-stage biotechnology company developing complement therapeutics, including its lead candidate DNTH103 which is in Phase 2 trials.

Got photos? Submit your photos here. ›

The takeaway

Braidwell LP's significant investment in Dianthus Therapeutics underscores the institutional confidence in the biotech firm's potential, as it advances its pipeline of complement-targeted therapies for autoimmune and inflammatory diseases. This influx of capital could provide Dianthus with the resources needed to accelerate its clinical development efforts.